Literature DB >> 26782210

Hypoxia-Driven Adenosine Accumulation: A Crucial Microenvironmental Factor Promoting Tumor Progression.

Peter Vaupel1, Arnulf Mayer2.   

Abstract

Systematic studies on the oxygenation status of solid tumors have shown that the development of hypoxic/anoxic tissue subvolumes is a pathophysiological trait in a wide range of human malignancies. As a result of this characteristic property, adenosine (ADO) accumulation (range: 50-100 μM) occurs caused by intra- and extracellular generation of ADO. Extracellular nucleotide catabolism by hypoxia-/HIF-1α-sensitive, membrane-associated ecto-5'-nucleotidases most probably is the major source of ADO in the halo of cancer cells upon specific genetic alterations taking place during tumor growth. Extracellular ADO can act through autocrine and paracrine pathways following receptor-binding and involving different intracellular signalling cascades. Hypoxia-driven receptor activation can lead to a broad spectrum of strong immune-suppressive properties facilitating tumor escape from immune control (e.g., inhibition of CD4+, CD8+, NK and dendritic cells, stimulation of Treg cells). In addition, tumor growth and progression is promoted by ADO-driven direct stimulation of tumor cell proliferation, migration, invasion, metastatic dissemination, and an increase in the production of molecules stimulating tumor angiogenesis. Hypoxia- driven ADO accumulation in the tumor microenvironment thus plays a critical role in tumor growth and progression at multiple pathophysiological levels.

Entities:  

Keywords:  Adenosine accumulation; Tumor growth; Tumor hypoxia; Tumor immune escape; Tumor progression

Mesh:

Substances:

Year:  2016        PMID: 26782210     DOI: 10.1007/978-1-4939-3023-4_22

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  24 in total

Review 1.  Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities.

Authors:  Peter Vaupel; Gabriele Multhoff
Journal:  Strahlenther Onkol       Date:  2016-03-09       Impact factor: 3.621

2.  Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.

Authors:  Alberto L Horenstein; Valeria Quarona; Denise Toscani; Federica Costa; Antonella Chillemi; Vito Pistoia; Nicola Giuliani; Fabio Malavasi
Journal:  Mol Med       Date:  2016-10-13       Impact factor: 6.354

Review 3.  Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.

Authors:  Alexander David Barrow; Marco Colonna
Journal:  Semin Immunol       Date:  2017-09-19       Impact factor: 11.130

Review 4.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 5.  Targeting adenosine in cancer immunotherapy: a review of recent progress.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Anticancer Ther       Date:  2017-04-27       Impact factor: 4.512

Review 6.  Cancer Metabolism: Fueling More than Just Growth.

Authors:  Namgyu Lee; Dohoon Kim
Journal:  Mol Cells       Date:  2016-12-29       Impact factor: 5.034

Review 7.  Accomplices of the Hypoxic Tumor Microenvironment Compromising Antitumor Immunity: Adenosine, Lactate, Acidosis, Vascular Endothelial Growth Factor, Potassium Ions, and Phosphatidylserine.

Authors:  Peter Vaupel; Gabriele Multhoff
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

Review 8.  Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers.

Authors:  Ross King; Conall Hayes; Claire L Donohoe; Margaret R Dunne; Maria Davern; Noel E Donlon
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

Review 9.  Pathophysiological Basis for the Formation of the Tumor Microenvironment.

Authors:  Michael R Horsman; Peter Vaupel
Journal:  Front Oncol       Date:  2016-04-12       Impact factor: 6.244

10.  Commentary: A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment.

Authors:  Peter Vaupel; Gabriele Multhoff
Journal:  Front Immunol       Date:  2016-08-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.